{
  "emaEpar": [
    {
      "activeSubstance": "sorafenib",
      "conditionIndication": "Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\u00fcrthle cell) thyroid carcinoma, refractory to radioactive iodine.",
      "inn": "sorafenib",
      "marketingAuthorisationDate": "2006-07-19 00:00:00",
      "marketingAuthorisationHolder": "Bayer AG",
      "medicineName": "Nexavar",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "Nexavar",
      "indication": "1 INDICATIONS AND USAGE NEXAVAR is a kinase inhibitor indicated for the treatment of \u2022 Unresectable hepatocellular carcinoma ( 1.1 ) \u2022 Advanced renal cell carcinoma ( 1.2 ) \u2022 Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 1.1 Hepatocellular Carcinoma NEXAVAR \u00ae is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.",
      "manufacturer": "Bayer HealthCare Pharmaceuticals Inc.",
      "splSetId": "b50667e4-5ebc-4968-a646-d605058dbef0"
    }
  ],
  "id": "Sorafenib",
  "nciThesaurus": {
    "casRegistry": "284461-73-0",
    "chebiId": "CHEBI:50924",
    "chemicalFormula": "C21H16ClF3N4O3",
    "definition": "A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.",
    "fdaUniiCode": "9ZOQ3TZI87",
    "identifier": "C61948",
    "preferredName": "Sorafenib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C159199",
      "C2336",
      "C93259"
    ],
    "synonyms": [
      "BA4 43 9006",
      "BAY 43-9006",
      "Bay-439006",
      "SORAFENIB",
      "Sorafenib",
      "sorafenib"
    ]
  }
}